Canaccord


Canaccord Reiterates A Buy On Lannett Company Following FDA Approval For Generic Codeine Sulfate

In a research note issued earlier today, Canaccord analyst John Newman reiterated coverage with a “Buy” rating on Lannett Company, Inc. (LCI), and a …

IMAX Corporation Reiterated With A Buy At Canaccord

In a research note issued earlier today, Canaccord analyst Aravinda Galappatthige maintained coverage with a “Buy” rating on IMAX Corporation (IMAX), and a price target of $34.50 a …

Canaccord Maintains Buy Rating On TW Telecom

In a research note issued earlier today, Canaccord analyst Gregory Miller maintained coverage with a “Buy” rating on TW Telecom Inc. (TWTC) and a price target of …

Canaccord Raises Price Target On Medifast; Expects Improved Profitability

In a research note released today, Canaccord analyst Scott Van Winkle maintained his Hold position on Medifast (MED) and upgraded his price target to $32.00 from $31.

OraSure Technologies Price Target Raised at Canaccord Following Agreement With AbbVie

In a research note issued today, Canaccord analyst Mark Massaro reiterated a Buy rating and boosted his price target on OraSure Technologies (OSUR) to $11.00 …

Valeant Pharmaceuticals Reiterated With A Buy At Canaccord

In a research note issued today, Canaccord maintained coverage with a “Buy” rating on Valeant Pharmaceuticals (VRX), and a price target of $168.00 a share.

Canaccord Downgrades B/E Aerospace to Hold As Company Sale Looks Incrementally Less Likely

In a research report issued today, B/E Aerospace Inc. (BEAV) was downgraded by analyst Kenneth Herbert at Canaccord from a “buy” rating to a “hold” rating.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts